Search

Virginiamycin M1

Pristinamycin IIA is a macrolide antibiotic, a member of the streptogramin A group of antibiotics, and one component of pristinamycin. It is produced by Streptomyces graminofaciens and other bacteria.

Piperaquine

Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China [A31550]. … Its use declined in the 1980's as piperaquine resistant strains of *Plasmodium falciparum* appeared and artemisinin derivatives became available.

Serdexmethylphenidate

[L32298, L32323] Serdexmethylphenidate was granted FDA approval on March 2, 2021, and is currently marketed as a combination capsule with [dexmethylphenidate] under the trademark AZSTARYS™ by KemPharm … [A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma

Upanovimab

Upanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19

Dexchlorpheniramine maleate

Dexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. … Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.

Novaferon

Bioallethrin

A mixture containing only S-forms of allethrin is referred to as esbioallethrin or S-bioallethrin. … A mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin.

Letermovir

It is currently marketed under the brand name Prevymis.[L1021] … [L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.

Abemaciclib

Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity … It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with [DB00947].

Natalizumab

Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. … [L48041] Natalizumab was approved by the European Commission on September 22, 2023.[L49096]